SCHEMBL25754005

SCHEMBL25754005

CCn1nnc2ccc(NC(=O)OC(C)(C)C)c(OC)c21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
ACSS2 Q9NR19 1/20 0.36
NR1I2 O75469 1/20 0.35
CYP17A1 P05093 2/20 0.35
BRD9 Q9H8M2 1/20 0.35
BRD4 O60885 1/20 0.34
HCAR3 P49019 1/20 0.33
CNR2 P34972 1/20 0.33
ABL1 P00519 2/20 0.33
SRC P12931 1/20 0.33
PIK3CD O00329 1/20 0.33
EGFR P00533 1/20 0.33
KDR P35968 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CG P48736 1/20 0.33
BACE1 P56817 1/20 0.33
PRKDC P78527 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
ELANE P08246 1/20 0.33
CTRB1 P17538 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25672474 0.80 MAPK1 (0.39) MAPTACSS2CYP17A1BRD9CNR2
SCHEMBL25754179 0.80 ACSS2 (0.36) MAPTACSS2CYP17A1BRD9CNR2
SCHEMBL30895067 0.80 ACSS2 (0.36) MAPTACSS2CYP17A1BRD9CNR2
SCHEMBL31017417 0.79 ACSS2 (0.42) MAPTACSS2BRD9BRD4ELANE
SCHEMBL25754261 0.79 ACSS2 (0.42) MAPTACSS2BRD9BRD4ELANE
SCHEMBL31017361 0.73 GSK3B (0.37) CNR2ABL1SRCPIK3CD
SCHEMBL25750456 0.73 GSK3B (0.37) CNR2ABL1SRCPIK3CD
SCHEMBL30895054 0.73 MAPK1 (0.36) ACSS2CYP17A1BRD9CNR2PIK3CD
SCHEMBL30895063 0.71 MAPK1 (0.38) CYP17A1BRD9ABL1SRCPIK3CD
SCHEMBL25758055 0.71 KDM4E (0.36) MAPTCYP17A1BRD9ABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885ACSS2 2376/4885NR1I2 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.